Crystal structure of bifunctional transglycosylase pbp1b from e. coli  and inhibitors thereof

ABSTRACT

The crystal structure at 2.16 Å resolution of the full-length bacterial bifunctional transglycosylase penicillin-binding protein 1b (PBP1b) from  Escherichia coli , in complex with its inhibitor moenomycin, is provided. The atomic coordinates of the complex as well as the moenomycin binding site are provided. Three dimensional structures of amino acid residues involved in moenomycin binding and transglycosylation activity are identified. Binding site for peptidoglycan synthesis inhibitors comprising inhibitor-binding site comprises amino acid residues from at least one of transglycosylase (TG), UvrB domain 2 homolog (UB2H) and transmembrane (TM) domains of PBP1b are identified at an atomic level of resolution. Methods for rational drug design based on the atomic coordinates are provided. Methods for screening for antibiotics based on anisotropic binding assay and transglycosylase inhibitor assays are provided. Novel antibiotics based on the screening assays of the invention are disclosed.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority of provisional patent applications U.S. Ser. No. 61/208,566, titled “Structure and Functional Aspects of the Bacterial Bifunctional Transglycosylase PBP1b From E. coli And Binding Interactions With Moenomycin” filed Feb. 25, 2009, and U.S. Ser. No. 61/135,503, titled “Structure and Functional Aspects of the Bacterial Bifunctional Transglycosylase PBP1b From E. coli And Binding Interactions With Moenomycin” filed Jul. 21, 2008, the contents of which are incorporated herein in their entirety by reference.

TECHNICAL FIELD OF THE INVENTION

The present invention relates to a bacterial bifunctional transglycosylase PBP1b from E. Coli, that can be co-crystallized with an inhibitory ligand such as moenomycin, and more particularly, to the detailed crystallographic data obtained from said co-crystallization which is disclosed herein. The invention also relates to methods of using the crystal structure and x-ray crystallographic coordinates of the moenomycin-bound bacterial bifunctional transglycosylase PBP1b to design, isolate and screen compounds which bind to the active site of E. coli PBP1b and inhibit transglycosylases and related proteins.

BACKGROUND OF THE INVENTION

Bacterial cell wall biosynthesis is one of the major targets where many antibiotics are designed and acted upon. The cell walls of both Gram-positive and -negative bacteria consist of layers of peptidoglycan, which has a mesh-like structure scaffolding the cytoplasmic membrane. Cell wall maintains the shape and integrity of bacteria. It can protect bacterial cells against osmotic pressure, and its disruption can lead to cell lysis and death. (Holtje, J. V. (1998). Microbiol Mol Biol Rev 62, 181-203.)

The discovery and clinical development of penicillin ushered in the modern antibiotic era and stimulated the discovery of the antibiotics in current clinical use. Some 80 years after their discovery, penicillins and related antibiotics (collectively called β-lactams) remain clinically useful. Nevertheless, the remarkable ability of bacteria to develop resistance to β-lactam and other antibiotics means that there is a continued need for new antibiotic targets and new antimicrobial agents. (Wright G D. Science (2007) 315(5817):1373-1374.)

Penicillin and other β-lactam antibiotics target several bacterial enzymes, collectively termed penicillin-binding proteins (PBPs). PBPs are necessary for the growth and maintenance of the peptidoglycan layer, which forms part of the bacterial cell wall and protects the cell from osmotic stress. Inhibition of peptidoglycan biosynthesis and of its controlled breakdown (for example, to enable partition of the cell wall during cell division) therefore inhibits cell growth. Because the peptidoglycan polymer is ubiquitous and essential to bacterial life, its assembly and maintenance are targets for many antibiotics.

Bacteria use a peptidoglycan layer to protect themselves from osmotic stress. Synthesis of this layer proceeds in several steps. First, lipid II is synthesized in the cell. It is then transferred to the outside, where it is added to the peptidoglycan polymer by membrane-associated transglycosylase enzymes. Finally, the polymer is cross-linked via interstrand peptide bonds catalyzed by transpeptidase enzymes.

The peptidoglycan consists of a backbone chain of repeating two-sugar units (called NAG and NAM) and a pentapeptide chain bound to each NAM (see the figure). The NAG-NAM-pentapeptide core (called lipid II) is synthesized in the cell and tethered to the cell membrane by a lipid linker. Lipid II is then transferred from the inside of the cell to the outside, where membrane-associated glycosyltransferases assist in grafting it onto the polymer. Transpeptidases catalyze the formation of peptide bonds between polymer strands, thereby making the wall more rigid. These tasks are performed by bifunctional enzymes that contain glycosyltransferase and transpeptidase domains; the latter are sensitive to β-lactams.

The glycosyltransferase activity of the bifunctional enzymes is an excellent target for the development of new antibiotics. The bifunctional enzymes include PBP1b from Escherichia coli. Despite their importance to bacterial physiology and drug discovery, they have resisted detailed study, mainly because these large membrane proteins are difficult to purify, assay, and crystallize.

The high-molecular-weight penicillin-binding proteins (PBPs) are responsible for the enlargement of the essential bacterial murein (peptidoglycan) sacculus by transpeptidation and transglycosylation of the murein precursors (Park, J. T. 1996. The murein sacculus, p. 48-57. In F. C. Neidhardt, et al. (ed.), Escherichia coli and Salmonella: cellular and molecular biology. ASM Press, Washington, D.C.). In E. coli there are three bifunctional enzymes catalyzing both reactions, PBP1a, PBP1b, and PBP1c, and two monofunctional transpeptidases, PBP2 and PBP3. (Höltje, J.-V. 1998. Microbiol. Mol. Biol. Rev. 62:181-203). PBP1a and PBP1b are the major bifunctional enzymes (Ishino, F., K. Mitsui, S. Tamaki, and M. Matsuhashi. 1980. Biochem. Biophys. Res. Commun. 97:287-293; Terrak, M., et al., 1999. Mol. Microbiol. 34:350-364.), and a deletion of both is lethal for the cell (Suzuki, H., Y. Nishimura, and Y. Hirota. 1978. Proc. Natl. Acad. Sci. USA 75:664-668). Encoded by a single gene (ponB or mrcB), PBP1b was shown to exist in three forms (α, β, and γ) which differ in the length of the short cytoplasmic part of the protein. (Nakagawa, J., and M. Matsuhashi. 1982. Biochem. Biophys. Res. Commun. 105:1546-1553).

PBP1a and PBP1b are not essential for cell growth, but cells lacking both enzymes are not viable, indicating that both have a similar, essential function that cannot be taken over by other murein synthases (Suzuki, H., Nishimura, Y., and Hirota, Y. (1978) Proc. Natl. Acad. Sci. U.S.A. 75, 664-668; Yousif, S. Y., Broome-Smith, J. K., and Spratt, B. G. (1985) J. Gen. Microbiol. 131, 2839-2845). Yet, mutants lacking either PBP1a or PBP1b show particular phenotypes, indicating that these synthases may play distinct roles during cell growth and division. For example, mutants without PBP1b are more sensitive to β-lactam antibiotics than mutants without PBP1a (Yousif, S. Y., Broome-Smith, J. K., and Spratt, B. G. (1985) J. Gen. Microbiol. 131, 2839-2845).

Escherichia coli PBP1b is a bifunctional transglycosylase, also known as peptidoglycan glycosyltransferase or murein synthase. It contains a transmembrane (TM) helix, two enzymatic domains—transglycosylase (TG) and transpeptidase (TP) (Goffin C, Ghuysen J M (1998). Microbiol Mol Biol Rev 62:1079-1093), and a domain composed of about 100 amino acid residues between TM and TG with unknown structure and functionality (FIG. 2B). For over 50 years, TP has been the main target for 2 most important classes of antibiotics: β-lactams (e.g., penicillin and methicillin) and glycopeptides (e.g., vancomycin). Not too long after they were introduced, resistant bacteria had emerged rapidly and caused serious medical problems. In contrast, resistant strains against moenomycin, the only natural inhibitor to TG from Streptomyces, have rarely been found. The development of new antibiotics against TG domains has been highly anticipated (Halliday J, et al. (2006) Biochem Pharmacol 71:957-967), and not until recently have the molecular structures of TG domain been available, even with the TM structure undefined.

During the years, resistance bacteria strains against two of the most important antibiotics, β-lactam (such as penicillin) and glycopeptide (such as vancomycin), have become a very serious medical problem in the treatment of bacterial infections. (Fisher, J. F., Meroueh, S. O. & Mobashery, S. (2005). Chem Rev 105, 395-424.; Pootoolal, J., et al. (2002). Proc Natl Acad Sci USA 99, 8962-7.) β-lactam and glycopeptide antibiotics target against the transpeptidation process, i.e. the action of transpeptidase.

Unlike the prevalence of antibiotic resistant bacterial strains against transpeptidase, resistance phenotype against transglycosylase has not been reported. There is only one reported inhibitor against transglycosylase, Moenomycin. Therefore, there is a need for new antibiotics against the transglycosylase domain of PBP1b.

SUMMARY OF THE INVENTION

In order to facilitate the new antibiotic discovery, the atomic-resolution three-dimensional structure of this membrane-bound enzyme is determined by X-ray crystallography. The crystal structure of the full-length bacterial bifunctional transglycosylase PBP1b from Escherichia coli, in complex with its inhibitor Moenomycin, is provided herein at 2.16 angstrom resolution. New findings from this structure, the comparison with previous available data and the implication for drug discovery are discussed.

The invention relates to a method for identifying a potential inhibitor compound for bacterial transglycosylase (peptidoglycan glycosyltransferase or murein synthase), the method comprising the steps of: (a) using a three-dimensional structure of PBP1b as defined by atomic coordinates according to FIGS. 8-1 through 8-117; (b) employing said three-dimensional structure to design or select said potential inhibitor such that said potential inhibitor is capable of binding to at least one amino acid in the active site of PBP1b transglycosylase; (c) synthesizing the potential inhibitor; (d) in an assay, contacting the potential inhibitor with the PBP1b transglycosylase in the presence of lipid II, or derivative thereof; and (e) determining the transglycosylase inhibitory activity of the potential inhibitor.

The invention relates to a method of using a co-crystal of an E. coli PBP1b transglycosylase enzyme with moenomycin A for screening for a novel drug capable of inhibiting a bacterial transglycosylase, wherein said crystal effectively diffracts X-rays for the determination of the atomic coordinates of said PBP1b-moenomycin complex to a resolution of greater than 2.16 Å, according to FIGS. 8-1 through 8-117, and wherein said method comprises: (a) selecting a potential ligand by performing rational drug design with the three-dimensional structure of the moenomycin binding site determined for the crystal; (b) in an assay, contacting the potential ligand with the ligand binding domain of the enzyme; and (c) detecting the binding potential of the potential ligand for the ligand binding domain, wherein the potential ligand is selected as a novel drug based on the potential ligand having a greater affinity for the ligand binding domain than that of a known drug.

In some aspects, the potential transglycosylase inhibitor is designed or selected using computer modeling. In some aspects, the potential transglycosylase inhibitor is designed de novo. In some aspects, the potential transglycosylase inhibitor is designed based on a known inhibitor. In some embodiments, the known inhibitor is moenomycin.

In some aspects, the transglycosylase active site comprises one or more of the amino acid residues E114, E171, E233, E290, S398, and S510.

In some aspects, the inhibitor-binding site comprises one or more of moenomycin-binding residues Thr269, Val273, Phe277, Tyr315, Gln318, Lys355, Gly356, and Ser 358 residues of PBP1b. In some embodiments, the inhibitor binding comprises a hydrogen-bonding interaction with one or more of Glu233, Gln271, Asn275, Lys355, Arg286, Glu290 and Ser358 residues of E. Coli PBP1b. Some inhibitor-binding site residues comprise hydrophobic interactions with the inhibitor compound. In one aspect the inhibitor binding site comprises the transmembrane (TM) domain of PBP1b. In some aspects the binding is mediated by at least some portion of the TM domain of PBP1b.

In some aspects, the inhibitor prevents peptidoglycan elongation by structurally mimicking lipid IV at the binding site of transglycosylase.

The invention further relates to a method of evaluating the binding properties of a potential PBP1b transglycosylase inhibitor compound comprising the steps of: (a) co-crystallizing said compound with PBP1b; (b) determining the three-dimensional structure of said PBP1b-potential inhibitor complex co-crystal by molecular replacement using the three-dimensional structure of PBP1b as defined by atomic coordinates according to FIGS. 8-1 through 8-117; and (c) analyzing said three-dimensional structure of said PBP1b bound to said potential inhibitor compound to evaluate the binding characteristics of said potential inhibitor compound.

The invention relates to method for identifying a potential inhibitor compound for E. coli Penicillin binding protein 1b (PBP1b) transglycosylase, the method comprising the steps of: (a) providing a candidate agent; (b) in an anisotropy measurement assay, determining an effectiveness of the candidate agent to bind PBP1b; and (c) in a transglycosylation assay, contacting the candidate agent with the PBP1b transglycosylase in the presence of lipid II and determining a PBP1b transglycosylase inhibitory activity of the candidate agent.

In some embodiments the method further comprises: (d) co-crystallizing said candidate agent with PBP1b; (e) determining the three-dimensional structure of said PBP1b—candidate agent complex co-crystal by comparing the three-dimensional structure of PBP1b—moenomycin as defined by atomic coordinates according to FIGS. 8-1 through 8-117; and (f) analyzing said three-dimensional structure of said PBP1b bound to said candidate agent to evaluate the binding characteristics of said potential inhibitor compound.

The invention relates to a candidate PBP1b inhibitory agent which is a compound of the formula:

In some aspects, the candidate PBP1b inhibitory agent is a compound of the formula (WCKTS-A1N1):

or the formula (WCKTS-A1N3):

In one aspect the candidate inhibitory agent is a compound of the formula:

wherein R¹═Br, Cl, I, H or OH;

R²═H, OH or Cl;

R³═Br, Cl, I, H, or

R⁴═H, OH, Cl,

R⁵═H, Cl,

R⁶═H, CH₃, OH, OCH₃, C₁, NO₂, or

and

R⁷═H, Cl,

wherein the compound (a) binds PBP1b, and (b) exhibits transglycosylase activity.

In one aspect, the binding of the candidate inhibitory agent to PBP1b requires at least a portion of the transmembrane (TM) domain.

The invention relates to anti-bacterial compounds comprising the general formula:

wherein R¹═Br, Cl, I, H or OH;

R²═H, OH or Cl;

R³═Br, Cl, I, H, or

R⁴═H, OH, Cl,

R⁵═H, Cl,

R⁶═H, CH₃, OH, OCH₃, C₁, NO₂, or

and

R⁷═H, Cl,

wherein the compound (a) binds PBP1b, and (b) exhibits transglycosylase activity.

The invention relates to anti-bacterial compounds comprising the general formula:

wherein the compound (a) binds PBP1b and (b) exhibits transglycosylase activity.

In some aspects, the anti-bacterial compound has the formula (WCKTS-A1N1):

In some aspects, the anti-bacterial compound has the formula (WCKTS-A1N3):

In some embodiment, the anti-bacterial compound is effective in inhibiting the growth of at least one of Staphylococcus aureus (ATCC29213, SA), methicillin-resistant Staphylococcus aureus (ATCC33592, MRSA), Mycobacterium smegmatis (ATCC11565, MS), and Escherichia coli (ATCC 25922, EC), Streptococcus pneumonia, Bacillus subtilis, Enterococcus faecalis, Acinetobacter baumannii, Pseudomonas aeruginosa, Aquifex aeolicus, and Stenotrophomonas maltophilia.

In some aspects, the anti-bacterial compound, in a co-crystal of the compound with PBP1b, the compound contacts the moenomycin-binding site of PBP1b as defined by atomic coordinates according to FIGS. 8-1 through 8-117.

In one aspect the anti-bacterial compound binds PBP1b in a binding interaction mediated by one or more residues of the transmembrane (TM) domain, UvrB domain 2 homolog (UB2H) domain, or transglycosylase (TG) domain of PBP1b.

In one aspect the anti-bacterial compound binds E. coli PBP1b by binding to at least one portion of the UvrB domain 2 homolog (UB2H) domain of PBP1b. In some embodiments, the UB2H binding further inhibits cell wall synthesis. In some embodiments, the UB2H binding further inhibits DNA repair.

In one aspect the anti-bacterial compound prevents peptidoglycan elongation by structurally mimicking lipid IV at the binding site of transglycosylase. In some embodiments, the compound inhibits a peptidoglycan glycosyltransferase. In some embodiments, the peptidoglycan glycosyltransferase is PBP1b, SaPBP2 or AaPGT.

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure, the inventions of which can be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein. The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

FIG. 1 shows the statistics of data collection and structure determination for the structure determination of E. coli PBP1b at 2.63 Å resolution.

FIG. 2 shows the overall structure and topology of E. coli PBP1b. (FIG. 2A) The crystal structure of PBP1b is represented as a ribbon diagram. The TM, UB2H, TG, and TP domains are color coded in cyan, yellow, red, and blue, respectively. Moenomycin is represented as van der Waals spheres. Tryptophan and tyrosine residues located near the water-membrane interfaces are shown in black sticks. The proposed membrane location is indicated by a gray rectangle. All figures of 3D structural representations were made with PyMOL (www.pymol.org). (FIG. 2B) The 1D and 2D topology of E. coli PBP1b are color-coded as in A. The numbering (1-5) at the N terminus of UB2H domain and the alphabet (A-E) at the C terminus of UB2H domain are markers for the locations used in the combinatorial domain deletion experiments.

FIG. 3 shows contact interface between the TM and TG domains of PBP1b. (3A) The TM and TG domains are shown in cyan and red, respectively. Contact residues are shown as sticks. (3B) Sequence alignment of the three transglycosylases PBP1b, PBP2 and AaPGT from E. coli, S. aureus, and A. aeolicus, respectively. The numbering indicates the sequential position of residues. Contact residues with moderate conservation are shaded in red.

FIG. 4 shows the amino acid residues in PBP1b interacting with moenomycin and structure-based sequence alignment of transglycosylases. (FIG. 4A) The potential hydrogen-bonding interactions (distance cutoff 3.2 Å) between E. coli PBP1b and moenomycin are shown as dashed lines in black. The interactions between the putative active sites (E233 and E290) and moenomycin proposed in ref. 6 are shown as dashed lines in red. (FIG. 4B) Comparison of moenomycin-binding modes between E. coli PBP1b and SaPBP2 (Left); between E. coli PBP1b and AaPGT (Right). TG and residues of E. coli PBP1b, SaPBP2, and AaPGT are shown in red, cyan, and green, respectively. Moenomycin are shown in light gray (for E. coli PBP1b) and dark gray (for SaPBP2 and AaPGT). (FIG. 4C) Sequences of TG from E. coli PBP1b, SaPBP2, and AaPGT are aligned according to their secondary structure elements. Residues forming the potential interaction with moenomycin are shaded in red.

FIG. 5 shows UB2H domain, its deletion phenotype and pull-down assay. (FIG. 5A) The structurally homologous domains from PBP1b, UvrB (PDB ID code 2NMV), and TRCF (PDB ID code 2EYQ) are shown in yellow, cyan, and magenta, respectively. The nonhomologous parts of these proteins are colored in gray. (FIG. 5B) Morphological differences and DNA segregation between the wild type and UB2H-truncated (PBP1b ΔUB2H) strains are shown in differential interference contrast microscopy combined with DAPI staining images. (Scale bar, 1 μm.) (FIG. 5C) Wild-type PBP1b, deletion mutant PBP1bΔUB2H, and UB2H domain only were coupled to CNBr-activated Sepharose, and their binding abilities to MltA, PBP3, and FtsN respectively, were examined.

FIG. 6 shows interdomain flexibility and a model for peptidoglycan synthesis. (FIG. 6A) E. coli PBP1b and 2 SaPBP2 conformers (Lovering A L, et al., (2007) Science 315:1402-1405; Lovering A L, et al. (2008) J Mol Biol 383:167-177) were indicated by colored, light gray (PDB ID code 3DWK), and dark gray (PDB ID code 2OLV), respectively. The TG domain of SaPBP2 was superimposed onto the TG of E. coli PBP1b. Side view (Left) and top view (Right) of the comparison reveals possible flexibility of a hinge region between TG and TP domains. (FIG. 6B) Active sites of TG and TP were shown by van der Waals spheres. The disaccharide, pentapeptide, and lipid tail of lipid II and peptidoglycan were shown in orange surface, green surface, and blue line, respectively. A single strand of the proposed peptidoglycan model (Meroueh S O, et al. (2006) Proc Natl Acad Sci USA 103:4404-4409) was docked onto the structure of E. coli PBP1b, with lipid IV portion replacing moenomycin. The incoming lipid II, of which the chemical structure is shown on top, diffuses in the plane of the membrane. After the TG reaction, the lipid moiety of this lipid II is kept as the membrane anchor, whereas the original lipid tail (shown as dotted line) is recycled. The polymerized peptidoglycan grows perpendicularly to the membrane and toward the TP domain, where the crosslinking reaction of the pentapeptides takes place.

FIG. 7 shows the amino acid sequence of E. coli PBP1b (SEQ ID NO: 1; amino acids 1-844; Swiss Prot Database accession number P02919).

FIGS. 8-1 through 8-117 lists the atomic structure coordinates for PBP1b as derived by X-ray diffraction from a crystal of PBP1b-moenomycin A complex at 2.16 Å resolution.

The foregoing and other objects, features and advantages of the invention will be apparent from the following more particular description of preferred embodiments of the invention, as illustrated in the accompanying drawings in which like reference characters refer to the same parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the invention.

DETAILED DESCRIPTION OF THE INVENTION

In the following description, reference is made to the accompanying drawings that form a part hereof, and in which is shown by way of illustration specific embodiments which may be practiced. These embodiments are described in detail to enable those skilled in the art to practice the invention, and it is to be understood that other embodiments may be utilized and that structural, logical and electrical changes may be made without departing from the scope of the present invention. The following description of example embodiments is, therefore, not to be taken in a limited sense, and the scope of the present invention is defined by the appended claims.

The transglycosylase domain of E. coli PBP1b, a multidomain membrane protein essential for cell wall synthesis, is an excellent target for the development of new antibiotics. The X-ray crystal structure of the bifunctional transglycosylase penicillin-binding protein 1b (PBP1b) from Escherichia coli in complex with its inhibitor moenomycin resolved to 2.16 Å resolution is provided. In addition to the transglycosylase and transpeptidase domains, the structure provides a complete visualization of this important target for designing antibacterial agents. A domain for protein-protein interaction and a transmembrane helix domain essential for substrate binding, enzymatic activity, and membrane orientation is disclosed.

The only known potent inhibitors for transglycosylase (TG) are moenomycin complexes (flavomycin), including moenomycin A (Moe A), A12, C1, C3, and C4. (Adachi M, et al. Degradation and reconstruction of moenomycin A derivatives: Dissecting the function of the isoprenoid chain. J Am Chem. Soc. 2006;128:14012-14013). Assays for binding of moenomycin to various truncated PBPs concluded that the transmembrane (TM) domain is critical for moenomycin binding. (Cheng et al., Proc Natl Acad Sci USA. 2008 Jan. 15; 105(2): 431-436.)

To grow the crystals of the present invention, the E. coli PBP1b and an inhibitory compound complex are purified to greater than 80% total protein and more preferably purified to greater than 90% total protein. For expression and purification purposes, the full-length PBP1b may be subcloned from E. coli chromosomal DNA preparation by the polymerase chain reaction (PCR) and inserted into an expression vector.

A large number of vector-host systems known in the art may be used. Possible vectors include, but are not limited to, plasmids or modified viruses, but the vector system must be compatible with the host cell used. Examples of vectors include E. coli bacteriophages such as lambda derivatives, or plasmids such as pBR322 derivatives or pUC plasmid derivatives, e.g., pGEX vectors (Amersham-Pharmacia, Piscataway, N.J.), pET vectors (Novagen, Madison, Wis.), pmal-c vectors (Amersham-Pharmacia, Piscataway, N.J.), pFLAG vectors (Chiang and Roeder, 1993, Pept. Res. 6:62 64), baculovirus vectors (Invitrogen, Carlsbad, Calif.; Pharmingen, San Diego, Calif.), etc. The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini, by blunt end ligation if no complementary cohesive termini are available or by through nucleotide linkers using techniques standard in the art. E.g., Ausubel et al. (eds.), Current Protocols in Molecular Biology, (1992). Recombinant vectors comprising the nucleic acid of interest may then be introduced into a host cell compatible with-the vector (e.g. E. coli, insect cells, mammalian cells, etc.) via transformation, transfection, infection, electroporation, etc. The nucleic acid may also be placed in a shuttle vector which may be cloned and propagated to large quantities in bacteria and then introduced into a eukaryotic cell host for expression. The vector systems of the present invention may provide expression control sequences and may allow for the expression of proteins in vitro.

In a preferred embodiment, the full length PBP1b is subcloned from E. coli chromosomal DNA preparation into pET15b (Novagen). In order, to construct PBP1b mutants PCR site directed mutagenesis may be employed with verification by DNA sequencing by methods known to those skilled in the art. The mutants of the present invention may be subcloned into a suitable expression vector and introduced into a host cell for protein production, as described above.

The PBP1b nucleic acids of the present invention may be subcloned into an expression vector to create an expression construct such that the resultant PBP1b molecule which is produced comprises a fusion protein wherein said fusion protein comprises a tag for ease of purification. As referred to herein, a “tag” is any additional amino acids which are provided in a protein either C-terminally, N-terminally or internally for the ease of purification, for the improvement of production or for any other purpose which may facilitate the goals of the present invention (e.g. to achieve higher levels of production and/or purification). Such tags include tags known to those skilled in the art to be useful in purification such as, but not limited to, His tag, glutathione-s-transferase tag, flag tag, mbp (maltose binding protein) tag, etc. In a preferred embodiment, the wild-type and mutant PBP1bs of the present invention are tagged with His₆ (see Example 1 below). Such tagged proteins may also be engineered to comprise a cleavage site, such as a thrombin, enterokinase or factor X cleavage site, for ease of removal of the tag before, during or after purification. Vector systems which provide a tag and a cleavage site for removal of the tag are particularly useful to make the expression constructs of the present invention.

The tagged PBP1b of the present invention may be purified by immuno-affinity or conventional chromatography, including but not limited to, chromatography employing the following: nickel or cobalt-purification resins, anion exchange chromatography, cation exchange chromatography, hydrophobic resins, gel filtration, antiflag epitope resin, reverse phase chromatography, etc. After purification, the PBP1b and PBP1b-inhibitor compound complex may be concentrated to greater than 1 mg/ml for crystallization purposes. In a preferred embodiment PBP1b and PBP1b-inhibitor complexes are concentrated to greater than 10 mg/ml for crystallization and in a particularly preferred embodiment, PBP1b and PBP1b-inhibitor complexes are concentrated to greater than 20 mg/ml.

In order to determine whether the purified PBP1b of the present invention demonstrate transglycosylase activity, the purified PBP1b and also any PBP1b-related protein may be assayed by any method known to those skilled in the art for the determination of said activity.

In another embodiment, the crystals of the present invention comprise purified wild-type PBP1b (SEQ ID NO:1) and are grown at or below room temperature, preferably at 16° C. by the hanging-drop vapor-diffusion method from a crystallization solution comprising one or more precipitants such as sodium formate. Any crystallization technique known to those skilled in the art may be employed to obtain the crystals of the present invention, including, but not limited to, batch crystallization, vapor diffusion (either by sitting drop or hanging drop) and micro dialysis. Seeding of the crystals in some instances may be required to obtain X-ray quality crystals. Standard micro and/or macro seeding of crystals may therefore be used.

The crystals of the present invention may form in the space group P2₁2₁2 in native form with unit dimensions of a=63.1 Å, b=288.5 Å, c=62.4 Å and α, β, γ=90, 90, 90 degrees. The crystals diffract to a resolution greater than 3.6 Å, preferably greater than 2.16 Å.

The determination of the structure of PBP1b and PBP1b bound to an inhibitory compound has enabled, for the first time, the identification of the active site of PBP1b.

The three-dimensional structural information and the atomic coordinates associated with said structural information of PBP1b bound to an inhibitory compound is useful in rational drug design providing for a method of identifying inhibitory compounds which bind to and inhibit the enzymatic activity of PBP1b and related proteins. Said method for identifying said potential inhibitor for an enzyme comprising transglycosylase activity comprises the steps of (a) using a three-dimensional structure of PBP1b as defined by its atomic coordinates listed in FIGS. 8-1 through 8-117; (b) employing said three-dimensional structure to design or select said potential inhibitor; (c) synthesizing said potential inhibitor; (d) contacting said potential inhibitor with said enzyme in the presence of an acetylated substrate; and (e) determining the ability of said inhibitor to inhibit said deacetylase activity.

The present invention permits the use of molecular design techniques to design, identify and synthesize chemical entities and compounds, including inhibitory compounds, capable of binding to the active site of PBP1b and PBP1b -related proteins. The atomic coordinates of inhibitor-bound PBP1b may be used in conjunction with computer modeling using a docking program such as GRAM, DOCK, HOOK or AUTODOCK (Dunbrack et al., 1997, Folding & Design 2:27 42) to identify potential inhibitors of PBP1b. This procedure can include computer fitting of potential inhibitors to the active site of PBP1b to ascertain how well the shape and the chemical structure of the potential inhibitor will complement the active site or to compare the potential inhibitors with-the binding of Moenomycin A in the active site. (See Bugg et al, 1998, Scientific American December: 92 98; West et-al., 1995, TIPS 16:67 74.) The potential inhibitors designed by modeling with a docking program may conform to the general formula related to Moenomycin. Computer programs may also be-employed to estimate the attraction, repulsion and steric hindrance of the PBP1b and potential inhibitor compound. Generally, the tighter the fit, the lower the steric hindrances, the greater the attractive forces, and the greater the specificity which are important features for a specific inhibitory compound which is more likely to interact with PBP1b and related proteins rather than other classes of proteins. These features are desired particularly where the inhibitory compound is a potential transglycosylase drug.

The compounds of the present invention may also be designed by visually inspecting the three-dimensional structure to determine more effective transglycosylase inhibitors. This type of modeling may be referred to as “manual” drug design. Manual drug design may employ visual inspection and analysis using a graphics visualization program such as “0” (Jones, T. A., Zhou, J. Y., Cowan, S. W., and Kjeldgaard, M., Improved method for building protein models in electron density maps and the location of errors in these models, Acta Crystallog., A47, 110 119.)

Initially potential inhibitor compounds can be selected for their structural similarity to Moenomycin by manual drug design. The structural analog thus designed can then be modified by computer modeling programs to better define the most likely effective candidates. Reduction of the number of potential candidates is useful as it may not be possible to synthesize and screen a countless number of variations compounds that may have some similarity to known inhibitory molecules. Such analysis has been shown effective in the development of HIV protease inhibitors (Lam et al., 1994, Science 263:380 384; Wlodawer et al., 1993, Ann. Rev. Biochem. 62:543 585; Appelt, 1993 Perspectives in Drug Discovery and Design 1:23 48; Erickson, 1993, Perspectives in Drug Discovery and Design 1:109 128. Alternatively, random screening of an small molecule library could lead to potential inhibitors whose inhibitory activity may then be analyzed by computer modeling as described above to better determine their effectiveness as inhibitors.

Copending U.S. patent application Ser. No. 12/354,717 discloses a method for initial screening, the method comprising obtaining a candidate for screening; carrying out an anisotropy measurement assay, such as fluorescent anisotropy, with a class A penicillin-binding protein comprising at least a transmembrane and a transglycosylase domains; and determining the effectiveness of the candidate as a transglycosylase inhibitor. U.S. patent application Ser. No. 12/354,717 is incorporated herein by reference in its entirety.

DEFINITIONS

Position specific iterative BLAST (PSI-BLAST) refers to a feature of BLAST 2.0 in which a profile (or position specific scoring matrix, PSSM) is constructed (automatically) from a multiple alignment of the highest scoring hits in an initial BLAST search. The PSSM is generated by calculating position-specific scores for each position in the alignment. Highly conserved positions receive high scores and weakly conserved positions receive scores near zero. The profile is used to perform a second BLAST search and the results of each “iteration” used to refine the profile. This iterative searching strategy results in increased sensitivity.

For the purposes of further describing the structure of PBP1b and PBP1b -related proteins, from the data obtained from the PBP1b crystals of the present invention, the definition of the following terms is provided:

The term “β sheet” refers to two or more polypeptide chains (or β strands) that run alongside each other and are linked in a regular manner by hydrogen bonds between the main chain C═O and N—H groups. Therefore all hydrogen bonds in a β-sheet are between different segments of polypeptide. Most β-sheets in proteins are all-parallel (protein interiors) or all-antiparallel (one side facing solvent, the other facing the hydrophobic core), Hydrogen bonds in antiparallel sheets are perpendicular to the chain direction and spaced evenly as pairs between strands. Hydrogen bonds in parallel sheets are slanted with respect to the chain direction and spaced evenly between strands.

The term “α helix” refers to the most abundant helical conformation found in globular proteins. The average length of an α helix is 10 residues. In an α helix, all amide protons point toward the N-terminus and all carbonyl oxygens point toward the C-terminus. The repeating nature of the phi, psi pairs ensure this orientation. Hydrogen bonds within an α helix also display a repeating pattern in which the backbone C═O of residue X (wherein X refers to any amino acid) hydrogen bonds to the backbone HN of residue X+4. The α helix is a coiled structure characterized by 3.6 residues per turn, and translating along its axis 1.5 Å per amino acid. Thus the pitch is 3.6.times.1.5 or 5.4 Å. The screw sense of α helices is always right-handed.

The term “loop” refers to any other conformation of amino acids (i.e. not a helix, strand or sheet). Additionally, a loop may contain bond interactions between amino acid side chains, but not in a repetitive, regular fashion.

Amino acid residues in peptides shall herein after be abbreviated as follows: Phenylalanine is Phe or F; Leucine is Leu or L; Isoleucine is Ile or I; Methionine is Met or M; Valine is Val or V; Serine is Ser or S; Proline is Pro or P; Threonine is Thr or T; Alanine is Ala or A; Tyrosine is Tyr or Y; Histidine is His or H; Glutamine is Gln or Q; Asparagine is Asn or N; Lysine is Lys or K; Aspartic Acid is Asp or D; Glutamic Acid is Glu or E; Cysteine is Cys or C; Tryptophan is Trp or W; Arginine is Arg or R; and Glycine is Gly or G. For further description of amino acids, please refer to Proteins: Structure and Molecular Properties by Creighton, T. E., W. H. Freeman & Co., New York 1983.

The term “positively charged amino acid” refers to any amino acid having a positively charged side chain under normal physiological conditions. Examples of positively charged amino acids are Arg, Lys and His. The term “negatively charged amino acid” refers to any amino acid having a negatively charged side chain under normal physiological conditions. Examples of negatively charged amino acids are Asp and Glu. The term “hydrophobic amino acid” refers to any amino acid having an uncharged, nonpolar side chain that is relatively insoluble in water. Examples of hydrophobic amino acids are Ala, Leu, Ile, Gly, Val, Pro, Phe, Trp and Met. The term “hydrophilic amino acid” refers to any amino acid having an uncharged, polar side chain that is relatively soluble in water. Examples of hydrophilic amino acids are Ser, Thr, Tyr, Asp, Gln, and Cys. The term “aromatic amino acid” refers to any amino acid comprising a ring structure. Examples of aromatic amino acids are His, S Phe, Trp and Tyr.

The term “charge relay system” refers to a His-Asp arrangement as described by Fersht & Sperling, 1973, J. Mol. Biol. 74:137 149; Blow et al., 1969, Nature 221:337 340.

The term “active site” comprises any or all of the following sites in PBP1b, the substrate binding site, the catalytic transglycosylation site, or the site where an inhibitor of PBP1b binds. The active site, as referred to herein, comprises one or more of E114, E171, E233, E290, 5398, and 5510 (FIG. 3).

In some embodiments, the active site is defined by the Moenomycin binding site and residues involved in hydrophobic contact with moenomycin. The active site comprises one or more of Thr269, Val273, Phe277, Tyr315, Gln318, Lys355, Gly356, and Ser 358 (FIG. 4). The active site may also involve Glu233, Arg286, Ser358 and Ile359 of E. Coli PBP1b.

Overall Structure of PBP1b-Moenomycin Complex

The crystal structures of two bacterial transglycosylases, a bifunctional transglycosylase from S. aureus (referred to as SaPBP2) and a transglycosylase domain from Aquifex aeolicus (referred to as AaPGT), have been determined recently with their TM domain or TM and TP domains removed, respectively (Lovering A L, de Castro L H, Lim D, Strynadka N C (2007) Science 315:1402-1405; Yuan Y, et al. (2007) Proc Natl Acad Sci USA 104:5348-5353; Yuan Y, et al. (2008) ACS Chem Biol 3:429-436). These structures revealed critical interactions between protein and moenomycin and served as good platforms for antibiotic development.

PBP1b from E. coli is a bifunctional enzyme containing both glycosyltransferase and transpeptidase acitivity (class A penicillin-binding protein). (Goffin, C. & Ghuysen, J. M. (1998). Microbiol Mol Biol Rev 62, 1079-93.) The sequence of PBP1b is composed of an N-terminal single-spanning transmembrane (TM) helix and a hitherto functionally-unknown insertion followed by the glycosyltransferase (TG) domain and the C-terminal transpeptidase (TP) domain. (Barrett, D. S., Chen, L., Litterman, N. K. & Walker, S. (2004). Biochemistry 43, 12375-81). The TM helix domain has been shown to be important for the binding between E. coli PBP1b and moenomycin (Cheng, T. J., et al., (2008). Proc Natl Acad Sci USA 105, 431-6). In addition, the full-length PBP1b has been found to show a substantially higher TG enzymatic activity than a TM truncated counterpart. (Id.)

Therefore, in this study, a purified full-length PBP1b possessing a similar level of enzymatic activity (k_(cat) is 3.14±0.236 s⁻¹, Km is 18.3±4.05 μM and kcat/Km is (1.74±0.3)×10⁵ M⁻¹s⁻¹) to previous studies (Schwartz B, Markwalder J A, Seitz S P, Wang Y, Stein R L (2002) Biochemistry 41:12552-12561) was used for structure determination by X-ray crystallography.

The amino acid sequence of E. coli PBP1b is shown in FIG. 7. (Swiss-Prot Database accession number P02919). The domains of PBP1b are defined as: transmembrane (TM, residues 64-87), transglycosylase (TG, residues 195-409) and transpeptidase (TP, residues 444-736).

E. coli PBP1b[aa58-aa804] was cloned, expressed, purified and co-crystallized with Moenomycin. Moenomycin A (1) is a potent antibiotic that inhibits bacterial cell wall synthesis by binding to the transglycosylases that catalyze formation of the carbohydrate chains of peptidoglycan. (van Heijenoort J. Glycobiology 2001; 11:25R-36R) Moenomycin is the only natural product inhibitor known to directly bind to these enzymes. Its distinctive mechanism of action is matched by its unusual structure. Moenomycin A consists of a highly functionalized pentasaccharide attached via a unique phosphoglycerate linkage to a polyprenyl chain.

The crystal structure of E. coli PBP1b in complex with moenomycin was solved at 3.6 Å resolution and at 2.16 Å resolution (FIG. 2A). The atomic coordinates and structure factors have been deposited in the Protein Data Bank, pdb.org, with PDB ID codes 3FWL and 3FWM respectively. (See FIGS. 8-1 through 8-117). The protein construct includes amino acid residues 58-804, containing TM, an unknown domain, TG, and TP domains. In the process to obtain protein crystals with good X-ray diffracting quality, the solubilization, purification, and crystallization steps for the manufacture of PBP1b required the use of multiple detergents, including N-dodecyl-β-D-maltopyranoside, N-decyl-β-D-maltopyranoside, and N-dodecyl-N,N-dimethylamine-N-oxide.

By using a multi wavelength anomalous dispersion (MAD) approach with crystals from seleno-methionine labeled proteins, the phase information was obtained to generate a protein electron density map. The structure was built from residues 66-800, except two loop regions with absent electron density (residues 249-267 and 399-406), and was refined to good quality with R_(work) and R_(free) values of 20.6% and 25.1%, respectively. The statistics of data collection and structure determination are shown in FIG. 1.

At the amino terminus, the TM domain consists of a single long helix, encompassing residues 66-96. The residues 83-88 in the TM helix are in close vicinity to residues 292-296 in the TG domain (FIG. 3A).

Comparison with S. aureus PBP2 and A. aeolicus AaPGT Structure.

Further examination of the corresponding residues in the TM helix and TG domains among homologous transglycosylases PBP1b, PBP2 and AaPGT from E. coli, S. aureus, and A. aeolicus, respectively reveal a moderate conservation of hydrophobic amino acid residues, suggesting that similar interactions between the TM and TG domains in other transglycosylases may occur (FIG. 3B).

The overall fold of the TG domain in the PBP1b structure, in complex with moenomycin, is highly similar to the transglycosylase structures from SaPBP2 and AaPGT. The RMSD is 1.53 Å for 145 Cα atoms between TG domains from E. coli PBP1b and SaPBP2, and 1.46 Å for 143 Cα atoms between E. coli PBP1b and AaPGT. However, the residues involved in potential interactions with moenomycin (defined with distance cutoff at 3.2 Å) showed similarities and differences in these transglycosylase structures (FIGS. 4B and 4C). The resemblance between the PBP1b structure and SaPBP2 may explain the observation that transglycosylases from E. coli and S. aureus share comparable binding affinity to moenomycin (Cheng T J, et al. (2008) Proc Natl Acad Sci USA 105 :431-436).

In addition, the interacting residues of the TG domain around the E ring, the F ring, the phosphate group, and the carboxylate group of moenomycin are more conserved than the interacting residues with the remaining parts (FIG. 3A). The conserved interacting residues in the binding pocket of transglycosylases can be considered as the most critical region to be studied in the process of antibiotic design. The result is in agreement with the previous findings to define the minimal pharmacophore in moenomycin, in which the EF-ring phosphoglycerate portion together with either the C or the D ring forms critical interactions with proteins (Yuan Y, et al. (2008) ACS Chem Biol 3:429-436).

Although A. aeolicus (Berezovsky I N, Shakhnovich E I (2005) Proc Natl Acad Sci USA 102:12742-12747), like E. coli, was classified as Gram-negative bacterium, the interaction pattern with moenomycin in AaPGT showed differences from the PBP1b structure and SaPBP2 (FIGS. 4B and 4C). It is noted that a positively charged Lys-137 residue in AaPGT can form an interaction with the carboxylate group of the phosphoglycerate in moenomycin, however, the corresponding interacting residue is a negatively charged residue glutamic acid in both the PBP1b structure and that of SaPBP2. The mutagenesis study also confirmed that the activity of AaPGT was nearly abolished after mutating Lys-137 to alanine (Yuan Y, et al. (2008) ACS Chem Biol 3:429-436). However, Lys-287 of E. coli PBP1b (corresponding to Lys-137 in AaPGT) seems to be less critical for the activity of peptidoglycan synthesis in E. coli, because the Lys-287 to alanine mutant still possessed 63% of wild-type activity, whereas the Glu-290-to-glutamine mutant displayed only 2% of wild-type activity (Terrak M, et al. (2008) J Biol Chem 283:28464-28470). Thus corresponding lysine residues act differently in A. aeolicus AaPGT and E. coli PBP1b.

The crystal structure of E. coli PBP1b represents a structural platform of transglycosylase, in particular for Gram-negative bacterial pathogens, for the development of antibiotics. Together with the 2 structures of transglycosylases from Grampositive (SaPBP2) and thermophilic bacteria (AaPGT), addition of the PBP1b structure completes the structural scope of transglycosylases across the bacterial spectrum.

Several compounds with molecular weights smaller than moenomycin have been reported to compete with the moenomycin and bind directly to the transglycosylase domain (9, 13). Although the inhibition efficiencies of these compounds to bacteria are lower than that of moenomycin, the structural information between these compounds and transglycosylase can be studied via molecular modeling or by X-ray crystallography using current E. coli PBP1b structure as a template for structure based drug design.

Structure and Function of UvrB Domain 2 Homolog (UB2H)

In addition to the TM, TG, and TP domains that are commonly found in bifunctional transglycosylases, an unexpected domain was observed in the PBP1b crystal structure (FIG. 2A). This domain, comprising residues 109-200, folds with a five antiparallel-stranded β-sheets (β2-β6) and one α-helix (α1) and forms more interactions with the TP domain (with buried surface area of 630.17 Å²) and less interactions with the TG domain (313.01 Å²). In comparison with the structure of SaPBP2, which shows no direct interactions between the TG and TP domain, addition of this extra domain makes E. coli PBP1b a more compact structure. By using Dali search (Holm L, et al. (2008) Bioinformatics 24:2780-2781), this domain was found to be structurally homologous to domains in UvrB (RMSD is 1.8 Å for 82 Cα atoms, with 24% sequence identity) and TRCF (transcription-coupled repair factor) (RMSD is 1.6 Å for 82 Cα atoms, with 14% sequence identity) (FIG. 3A). UvrB and TRCF are critical components of nucleotide excision repair (NER) system in DNA damage repairs. (Truglio J J, et al. (2004) EMBO J. 23:2498-2509; Deaconescu A M, et al. (2006) Cell 124:507-520). The corresponding homologous domains in UvrB and TRCF specifically bind to a domain in UvrA in a competitive manner to coordinate the functionality of bacterial NER system. Based on the highly similar fold, this domain is referred to as UB2H (UvrB domain 2 homolog) domain.

Function of UvrB Domain 2 Homolog (UB2H)

UB2H deletion mutants of PBP1b were then constructed to gain insights into their functions (FIG. 2B). The mutant PBP1bΔUB2H (Glu-114 to Gln-191 were deleted) provided on a plasmid was found to be able to rescue a PBP1b-deletion/PBP1a-temperature-sensitive E. coli host strain, JE5702, at 42° C. At this temperature, both PBP1b and PBP1a are not functional; thus, the survival of JE5702 indicated that PBP1b ΔUB2H can complement the enzymatic functions of TG and TP. However, it was observed that UB2H deletion caused an aberrant growth rate and an elongated cell shape containing multiple copies of DNA in JE5702 (FIG. 5B).

In E. coli, PBP1b interacts with different proteins during the course of cellular growth and division. For example, MltA, the membrane-bound lytic transglycosylase, interacts with PBP1b and participates in the peptidoglycan processing during cell elongation and cell division (Vollmer W, von Rechenberg M, Holtje J V (1999) J Biol Chem 274:6726-6734); PBP3, a transpeptidase catalyzing the formation of cross-linked peptidoglycan, interacts with PBP1b for peptidoglycan synthesis during cell division (Bertsche U, et al. (2006) Mol. Microbiol. 61:675-690); FtsN, the essential cell division protein that can interact with PBP1b, may play a role in stabilizing the divisome during cell division (Muller P, et al. (2007) J. Biol. Chem. 282:36394-36402). To test whether UB2H serves as the binding domain in PBP1b for the interaction with different binding partners, pull-down assay was performed, and the result showed that PBP1bΔUB2H lost the binding ability with protein MltA, but not PBP3 or FtsN (FIG. 5C). In addition, the UB2H domain alone possessed binding ability similar to wild-type PBP1b, indicating that the UB2H domain participates in the interaction with MltA.

The UB2H domain exists only in bifunctional transglycosylases of some Gram-negative bacteria (183 of 988 bacterial genomes in the National Center for Biotechnology Information database as of November 2008). The protein-protein interaction between PBP1b and MltA established by the pull-down assay can be via a third protein MipA involved in bacterial cell-wall synthesis (Vollmer W, von Rechenberg M, Holtje J V (1999) J Biol Chem 274:6726-6734). A previous study, however, has reported that a mltA deletion did not affect the morphology of E. coli (Lommatzsch J, Templin M F, Kraft A R, Vollmer W, Holtje J V (1997) J Bacteriol 179:5465-5470). Thus, the aberrant morphology caused by UB2H deletion may not have a direct correlation to MltA. Other UB2H-interacting proteins can be involved in this morphological change. PBP1b, like UvrB and TRCF, can also interact with UvrA in a pull-down assay. The UB2H domain may participate in the regulation between DNA repair and/or synthesis and cell wall formation during the bacterial cell cycle.

Orientation of PBP1B in the Membrane

This PBP1b structure represents the first full-length PBP structure with the TM helix, which sheds insight on the orientation of the PBP1b molecule in the lipid bilayer. The presence of the TM helix in the PBP1b structure allows postulation of the orientation of the E. coli PBP1b molecule in lipid bilayers. It is commonly accepted that tryptophan and tyrosine residues have a higher frequency to be found at the lipid-water interface in membrane proteins (Yau W M, Wimley W C, Gawrisch K, White S H (1998) Biochemistry 37:14713-14718). All plausible tryptophan and tyrosine residues in the TG domain and TM helix were examined and a plane was found consisting of tryptophan and tyrosine residues that might be associated with lipids (FIG. 2A). As a result, the established membrane orientation made the bottom of the TG domain partially embedded in lipid bilayers. Also, based on this model, the C terminus of the TM helix (residues 88-96; 2 helical turns) is not embedded in the membrane.

The membrane orientation model was validated using molecular dynamics (MD) simulations (Lindahl E, Sansom M S (2008) Curr Opin Struct Biol 18:425-431). In the MD simulations, the proposed orientation of E. coli PBP1b in lipid bilayers was observed to be energetically stable in different MD simulations, and also suggested that the contact between TM and TG is not an artifact caused by crystal packing

The E. coli TP domain closely resembles the corresponding region in the SaPBP2 structure; however, the relative orientation between the TG and TP domains are dissimilar between our structure and SaPBP2 (FIG. 6A) (Lovering A L, de Castro L H, Lim D, Strynadka N C (2007) Science 315:1402-1405; Lovering A L, De Castro L, Strynadka N C (2008) J Mol Biol 383:167-177). Despite the discrepancy, we considered all different orientations plausible because of the possibly inherent flexibility of a hinge region (Lovering A L, De Castro L, Strynadka N C (2008) J Mol Biol 383:167-177). Different crystal structures can simply represent different structural states of the bifunctional transglycosylases. The changes in the relative orientation of SaPBP2 had been proposed to be correlated to the regulation of TG activity (Lovering A L, De Castro L, Strynadka N C (2008) J Mol Biol 383:167-177).

It has been observed that the binding affinity of moenomycin to E. coli PBP1b is TM domain dependent (Cheng T J, et al. (2008) Domain requirement of moenomycin binding to bifunctional transglycosylases and development of high-throughput discovery of antibiotics. Proc Natl Acad Sci USA 105:431-436.). However, no direct interaction between moenomycin and the TM helix was observed in our crystal structure. Furthermore, removal of the TM helix does not affect the structure of TG domain in the binding site, when comparing our structure and SaPBP2 in their moenomycin binding pockets (FIG. 4A). We therefore suggest that the TM helix simply stabilizes the protein membrane interaction, and the resulting orientation limits the interaction between PBP1b and moenomycin or lipid II in the membrane in a 2D lateral diffusion fashion. Removal of TM may destabilize the protein-membrane interaction, thus affecting moenomycin or lipid II binding to TG. Indeed, stable protein-membrane interaction has been reported recently to be crucial for the normal function of some membrane proteins, and hence it has been suggested to be a target for drug discovery (Segers K, et al. (2007) Design of protein membrane interaction inhibitors by virtual ligand screening, proof of concept with the C2 domain of factor V. Proc Natl Acad Sci USA 104:12697-12702.).

A Model for Peptidoglycan Synthesis.

It has been proposed that the moenomycin molecule in the binding site of transglycosylase structurally mimics lipid IV, the dimerized peptidoglycan from 2 molecules of lipid II, and suggested a mechanism of peptidoglycan elongation where the growing glycan chain acts as an acceptor for the nucleophilic attack with lipid II as a donor. (Lovering A L, de Castro L H, Lim D, Strynadka N C (2007) Science 315:1402-1405; Lovering A L, De Castro L, Strynadka N C (2008) J Mol Biol 383:167-177). Recently, the architecture of peptidoglycan has been modeled based on the NMR structure of a lipid IV derivative (Meroueh S O, et al. (2006) Proc Natl Acad Sci USA 103:4404-4409). Using the proposed peptidoglycan model, a single strand of the peptidoglycan was docked onto the structure of E. coli PBP1b, with the lipid IV portion replacing moenomycin (FIG. 6B). It is noted that the distance (65.8 Å) between the active-site residues of the TG and TP domains in the structure corresponds well to the distance (67.1 Å) between the reaction sites on the peptidoglycan. In this model, the surface of PBP1b in contact with peptidoglycan is largely composed of loops, which are possibly flexible and capable of accommodating the polymerizing peptidoglycan. Therefore, the membrane orientation of PBP1b established by the transmembrane helix implies that its product, peptidoglycan, can be synthesized perpendicularly to the membrane surface. In contrast to the conventional views that cell wall consists of layers of cross-linked peptidoglycans with their glycan backbones lying parallel to the membrane surface, the PBP1b structure and model suggest the possibility of vertical orientation of peptidoglycans at the membrane surface, at least when they are initially synthesized. There is, however, intrinsic flexibility in both the bifunctional transglycosylases and their product peptidoglycan strands. As the peptidoglycans grow longer, the complete polymerized and cross-linked cell wall may have different appearance where the peptidoglycan strands lie parallel to the membrane surface or even form a coiled-coil cable as demonstrated by recent electron microscopic studies (Gan L, Chen S Y, Jensen G J (2008) Proc Natl Acad Sci USA 105:18953-18957; Hayhurst E J, Kailas L, Hobbs J K, Foster S J (2008) Proc Natl Acad Sci USA 105:14603-14608).

Transglycosylase Inhibitors

Any method known to the skilled artisan may be employed to design a transglycosylase inhibitor by molecular replacement. For example, the program AMORE (The CCP4 suite: Programs for computational crystallography, 1994, Acta Crystallogr. D. 50:760-763) may be employed to determine the structure of PBP1b+/−a candidate inhibitor by molecular replacement using the PBP1b-moenomycin coordinates (FIGS. 8-1 through 8-117). For the structure determination of the candidate inhibitory compound, stereochemical restraints may be used in the refinement with the program CNS (Brunger et al., 1998, Acta Crystallogr. D 54:905 921).

A library was tested for transglycosylation inhibition by using fluorescence anisotropy binding assays, followed by transglycosylation enzymatic analysis. One small molecule (Compound 009) showed inhibition activities in both fluorescence anisotropy (as discussed in co-pending U.S. App. Ser. No. 12/354,717) and lipid II polymerization assays for transglycosylation activity. The IC₅₀ value of transglycosyaltion inhibition of Compound 009 is 45 μM.

Structure of the transglycosylase inhibitor Compound 009 is shown below:

Anti-bacterial activities of the compound are shown in Table 1. The compounds were tested against Staphylococcus aureus (ATCC29213, SA), methicillin-resistant Staphylococcus aureus (ATCC33592, MRSA), Mycobacterium smegmatis (ATCC11565, MS), or Escherichia coli (ATCC 25922, EC).

TABE 1 Anti-bacterial activities of Compound 009 MIC (μg/ml) SA MRSA MS EC Compound 009 O.5 O.25 0.25 >256

Several analogs were further obtained to study the structure-activity relationship (SAR) for transglycosylation inhibition activities. A general synthesis scheme is shown below with characterization of two example compounds.

Treatment of acid 1 (1 eq) and amine 2 (0.9 eq) in the presence of PCl₃ (1 eq) under microwave heating in toluene, followed by extraction and purification gave the desired product in a 30-75% yield range. The purified compounds were analyzed and characterized with NMR and LC-MS. For the preparation of acid 1 and amine 2, several chemical transformations are utilized such as nucleophilic aromatic substitution, alkylation, and halogenation.

Two compounds were selected:

¹H NMR (CDCl₃): δ 12.02 (s, 1H), 8.62 (s, 1H), 8.48 (d, 1H, J=2.4 Hz), 7.79 (d, 1H, J=2.4 Hz), 7.43-6.80 (m, 8H). HRMS calculate for [C₁₉H₁₂Br₂ClNO₃+H]⁺ 497.89, found 497.892.

¹H NMR (D-acetone): δ 10.17 (s, 1H), 8.21 (d, 1H, J=1.9 Hz), 7.91 (d, 1H, J=1.9 Hz), 7.86 (d, 1H, J=1.8 Hz), 7.58 (dd, 1H, J=8.2, 1.8 Hz), 7.33 (d, 1H, J=8.2 Hz), 2.33 (s, 3H). HRMS calculate for [C₁₄H₁₀Br₂ClNO₂+H]⁺ 419.88, found 419.881.

Transglycosylase Inhibition and Antibacterial Activity of Analogs

The structure and the summarized results are shown in Tables 2-4. The hydroxyl group of ring A is critical for the activity since the methylation of the hydroxyl group abolished the transglycosylase inhibition activity. The hit and its analogues were also confirmed to be active against Staphylococcus aureus (SA), methicillin-resistant Staphylococcus aureus (MRSA), and Mycobacterium smegmata (MS) as shown in Tables 5-7. The inhibitory activities of all potential inhibitor compounds listed in Tables 2-7 are subsequently analyzed by computer modeling as described above to better determine their effectiveness as inhibitors.

TABLE 2 Preliminary SAR of Salicylanilides.

TG Activity at various concentration of cmpd Cmpd R¹ R² R³ R⁴ R⁵ R⁶ R⁷ 100 μM 50 μM 25 μM 001 Br H Br H Cl Cl Cl 100% — — 003 Cl H Cl H Cl Cl H 100% — — 004 Cl H Cl H Cl Cl Cl 100% — — 142 Cl H Cl H Cl Cl Cl — — — 118 Br H Br H H Cl H 100% 100% — 127 Br H Br Cl H H Cl 100% 100% — 203 Br H Br H H H Cl 100% 100% — 141 Cl H Cl Cl H H Cl — — — 115 Br H Br Cl

H Cl   0% 100% — 116 Br H Br Cl

H Cl   0% 100% — 117 Br H Cl Cl

H Cl   0% 100% — 145 Br H Br Cl

H Cl   0% 100% — 122 Br H Br H H

Cl   0%  60% — 123 Br H Cl Cl H Cl

  0%  60% — 124 Br H Br H H Cl

  0% 100% — KTS-1 Br H Br H H OH H —  70% — KTS-3 Br H Br OH H H H —  70% — KTS-7 Br H Br H Cl CH₃ H 100% 100% — KTS-9 Br H Br H H Cl H 100% 100% — A1N3 Br H Br H Cl CH₃ H — 100% — A1N4 Br H Br H H Cl H — 100% — A3N3 H H H H Cl CH₃ H 100% 100% — A3N4 H H H H H Cl H 100% 100% — A3N5 H H H H H NO₂ H 100% 100% — A3N6 H H H H H OCH₃ H 100% 100% — A5N3 OH OH H H Cl CH₃ H   0% 100% —

TABLE 3 Preliminary SAR of Salicylanilides.

TG Activity at various concentration of cmpd Cmpd R¹ R² R³ R⁴ R⁵ R⁶ R⁷ 100 μM 50 μM 25 μM 009 Br H Br

H H Cl 0% 20% 100% 201 I H I

H H H —   0% 30% 202 Br H Br

H Cl H —   0% 20% 204 Br H Br

H H H —   0% 50% 205 H H Cl

H H Cl —  90% — 121 Br H Cl

H H Cl 0%   0% 90% 206 Br H Cl

H H Cl —   0% 60% 207 I H I

H H

—   0% 20% 208 I H I

H H Cl —   0% 100% 209 Cl H Cl

H H Cl —   0% 60% A1N2 Br H Br

H H H 100% 100% — A3N1 H H H

H H Cl 100% 100% — A3N2 H H H

H H H 100% 100% — A5N1 OH OH H

H H Cl 0% 100% — A5N2 OH OH H

H H H 0% 100% —

TABLE 4 Preliminary SAR of Salicylanilides.

TG Activity at various concentration of cmpd Cmpd R¹ R² R³ R⁴ R⁵ R⁶ R⁷ 100 μM 50 μM 25 μM 126* H Cl

OH H H Cl 100% 100% — A2N1* Br H Br

H H Cl 100% 100% — A2N2* Br H Br

H H H 100% 100% — A2N3* Br H Br H Cl CH₃ H 100% 100% — A4N1* H H H

H H Cl 100% 100% — A4N3* H H H H Cl CH₃ H 100% 100% — A6N1* H OH H

H H Cl 100% 100% — A6N2* H OH H

H H H 100% 100% — A6N3* H OH H H Cl CH₃ H 100% 100% —

The compounds were tested against Staphylococcus aureus (ATCC29213, SA), methicillin-resistant Staphylococcus aureus (ATCC33592, MRSA), Mycobacterium smegmatis (ATCC 11565, MS), or Escherichia coli (ATCC 25922, EC) as shown in Table 5 below.

TABLE 5 Anti-bacterial activities of the compounds shown in Table 5.

MIC (μg/ml) Cmpd R¹ R² R³ R⁴ R⁵ R⁶ R⁷ SA MRSA MS EC 001 Br H Br H Cl Cl Cl ≦0.03 0.06 ≦0.03 16 003 Cl H Cl H Cl Cl H 0.25 1 0.06 32 004 Cl H Cl H Cl Cl Cl 0.125 0.5 ≦0.03 16 142 Cl H Cl H Cl Cl Cl 0.5 0.5 0.125 — 118 Br H Br H H Cl H 1 4 1 128 127 Br H Br Cl H H Cl 1 1 1 64 203 Br H Br H H H Cl 2 2 4 — 141 Cl H Cl Cl H H Cl 1 0.5 2 — 115 Br H Br Cl

H Cl 0.5 2 0.25 >256 116 Br H Br Cl

H Cl 1 8 0.5 >256 117 Br H Cl Cl

H Cl 0.5 0.5 0.25 >256 145 Br H Br Cl

H Cl >4 >4 >4 — 122 Br H Br H H

Cl 0.5 0.25 0.125 >256 123 Br H Cl Cl H Cl

0.25 0.25 0.06 >256 124 Br H Br H H Cl

1 1 1 >256 KTS-1 Br H Br H H OH H 32 >32 16 — KTS-3 Br H Br OH H H H 4 4 4 — KTS-7 Br H Br H Cl CH₃ H 1 1 1 — KTS-9 Br H Br H H Cl H 1 1 2 — A1N3 Br H Br H Cl CH₃ H 1 — — — A1N4 Br H Br H H Cl H 1 — — — A3N3 H H H H Cl CH₃ H 4 — — — A3N4 H H H H H Cl H 8 — — — A3N5 H H H H H NO₂ H 4 — — — A3N6 H H H H H OCH₃ H >32 — — — A5N3 OH OH H H Cl CH₃ H 4 — — —

The compounds were tested against Staphylococcus aureus (ATCC29213, SA), methicillin-resistant Staphylococcus aureus (ATCC33592, MRSA), Mycobacterium smegmatis (ATCC 11565, MS), or Escherichia coli (ATCC 25922, EC) as shown in Table 6 below.

TABLE 6 Anti-bacterial activities of the compounds shown in Table 6.

MIC (μg/ml) Cmpd R¹ R² R³ R⁴ R⁵ R⁶ R⁷ SA MRSA MS EC 009 Br H Br

H H Cl 0.5 0.25 0.25 >256 201 I H I

H H H 4 2 8 — 202 Br H Br

H Cl H 1 1 1 — 204 Br H Br

H H H 1 4 8 — 205 H H Cl

H H Cl 0.5 0.5 1 — 121 Br H Cl

H H Cl 0.25 0.125 0.25 >256 206 Br H Cl

H H Cl 1 0.5 1 — 207 I H I

H H

8 4 32 — 208 I H I

H H Cl 4 0.5 2 — 209 Cl H Cl

H H Cl 1 0.25 0.5 — A1N2 Br H Br

H H H >32 — — — A3N1 H H H

H H Cl 1 — — — A3N2 H H H

H H H 8 — — — A5N1 OH OH H

H H Cl 8 — — — A5N2 OH OH H

H H H 8 — — —

The compounds were tested against Staphylococcus aureus (ATCC29213, SA), methicillin-resistant Staphylococcus aureus (ATCC33592, MRSA), Mycobacterium smegmatis (ATCC 11565, MS), or Escherichia coli (ATCC 25922, EC) as shown in Table 7 below.

TABLE 7 Anti-bacterial activities of the compounds shown in Table 7.

MIC (μg/ml) Cmpd R¹ R² R³ R⁴ R⁵ R⁶ R⁷ SA MRSA MS EC 126 H Cl

OH H H Cl 1 0.125 0.06 >256 A2N1 Br H Br

H H Cl >32 — — — A2N2 Br H Br

H H H >32 — — — A2N3 Br H Br H Cl CH₃ H >32 — — — A4N1 H H H

H H Cl >32 — — — A4N3 H H H H Cl CH₃ H >32 — — — A6N1 H OH H

H H Cl 16 — — — A6N2 H OH H

H H H >32 — — — A6N3 H OH H H Cl CH₃ H 32 — — —

Pharmaceutical Compositions

The instant disclosure also provides pharmaceutical compositions. In some implementations, the pharmaceutical compositions comprise agents, namely moenomycin analogs and small molecules (TG Inhibitors) shown to have antibiotic activity via inhibition of TG binding. In such pharmaceutical compositions, the TG Inhibitors form the “active compound” or “agent.” According to implementations, the pharmaceutical compositions are administered to a subject to in need of anti-bacterial therapy, including gram-negative bacteria. According to other implementations, the pharmaceutical compositions are administered to a subject having a bacterial infection to inhibit the transgylcosylation process during the synthesis of bacterial cell wall.

In addition to active compound, the pharmaceutical compositions preferably comprise at least one pharmaceutically acceptable carrier. As used herein the language “pharmaceutically acceptable carrier” includes solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Supplementary active compounds can also be incorporated into the compositions. A pharmaceutical composition is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Subject as used herein refers to humans and non-human primates (e.g., guerilla, macaque, marmoset), livestock animals (e.g., sheep, cow, horse, donkey, pig), companion animals (e.g., dog, cat), laboratory test animals (e.g., mouse, rabbit, rat, guinea pig, hamster), captive wild animals (e.g., fox, deer) and any other organisms who can benefit from the agents of the present disclosure. There is no limitation on the type of animal that could benefit from the presently described agents. Human subjects are expressly contemplated. A subject regardless of whether it is a human or nonhuman organism may be referred to as a patient, individual, animal, host, or recipient.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water-soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition should be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules, e.g., gelatin capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash. Pharmaceutically compatible binding agents, or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from a container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer. Other delivery methods and devices common in the art, including mechanically actuated atomizing-like devices are expressly contemplated.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For epidermal, dermal, or transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one implementation, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to cell-specific antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811, incorporated by reference herein.

It is advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.

Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Compounds which exhibit high therapeutic indices are preferred. While compounds that exhibit toxic side effects can be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in subjects. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage can vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the disclosure, the therapeutically effective dose can be estimated initially from cell culture assays. A dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC₅₀ (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in subjects. Levels in plasma can be measured, for example, by high performance liquid chromatography.

As defined herein, a therapeutically effective amount of an active compound of the disclosure may range, for examples, from about 0.001 to 30 mg/kg body weight, about 0.01 to 25 mg/kg body weight, about 0.1 to 20 mg/kg body weight, or about 1 to 10 mg/kg, 2 to 9 mg/kg, 3 to 8 mg/kg, 4 to 7 mg/kg, or 5 to 6 mg/kg body weight. Without limitation, the active compound can be administered between one time per week and three or more times per day, for between about 1 to 10 weeks, for example between 2 to 8 weeks, between about 3 to 7 weeks, or for about 4, 5, or 6 weeks. The skilled artisan will appreciate that certain factors can influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a pharmaceutical composition of the disclosure can include a single treatment or, preferably, can include a series of treatments.

For those agents determined to be transglycosylation inhibitors or antibiotics, further testing may then be performed for the candidate agent to determine agents that are both good transglycosylation inhibitors and also having reasonably bioavailability.

EXAMPLES

The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

Example 1 Cloning, Expression and Purification of PBP1b

Purified PBP1b gamma degraded readily into a slightly smaller protein. After N-terminal sequencing accompanying with molecular weight measurement by MALTI-TOF Mass spectrometry, we identified the stable region containing amino acid 58 to 804.

PBP1b[58-804] was amplified from E. coli genomic DNA and cloned into the expression vector pET15b (NovagEN; EMD Sciences, San Diego, Calif.)) at the NdeI and BamHI restriction sites. BL21(DE3) E. coli host cells were grown at 37° C. until OD₆₀₀ reached 0.6, and protein expression was induced with 1 mM IPTG for 3 hr. Cell pellets were resuspended in 20 mM Tris at pH 8.0, 300 mM NaCl and broken by Microfluidizer™ (Microfluidics, Newton, Mass.). Recombinant protein with an N-terminal (His)₆ tag was solubilized with 20 mM n-Dodecyl-β-D-maltoside (DDM; Anatrace, Maumee, Ohio, USA)) and purified by nickel chelation chromatography, in accordance with the manufacturer's instructions, in the presence of 1 mM DDM. An N-terminal (His)₆ tag was cleaved by thrombin (Sigma) at room temperature for overnight. Digested PBP1b was further purified using a Superdex 200™ size-exclusion column (GE Biosciences) in 20 mM Tris at pH 8.0, 300 mM NaCl, 4.5 mM DM. Peak fractions were concentrated and the detergent was exchanged to 0.28 mM LDAO using Amicon™ Ultra filter units (Millipore, Billerica, Mass.). The selenomethionine (SeMet) derivative was expressed in BL21(DE3) using minimal medium supplemented with selenomethionine and purified as described above.

Example 2 Crystallization, Data Collection and Structure Determination

Crystals of PBP1b[58-804]-Moenomycin complex were co-crystallized in sitting drop at 16° C. Crystals were obtained by mixing 12 mg/ml protein containing additional 1.4 mM moenomycin with the same volume of reservoir solution containing 1.2 M sodium formate. For cryoprotection, crystals were transferred into 3 M sodium formate and flash-frozen in liquid nitrogen.

Native dataset was collected at Beamline 44XU™ of Japan Synchrotron Radiation Research Institute (Hyogo, J P) and SeMet datasets were collected at Beamline 13B1™ of National Synchrotron Radiation Research Center (Hsinchu, T W). All data were indexed, integrated and scaled with HKL2000. (Leslie, A. G., Powell, H. R., Winter, G., Svensson, O., Spruce, D., McSweeney, S., Love, D., Kinder, S., Duke, E. & Nave, C. (2002). Automation of the collection and processing of X-ray diffraction data—a generic approach. Acta Crystallogr D Biol Crystallogr 58, 1924-8.) MAD method was used to collect anomalous datasets from SeMet derivative. The selenium sites (22 out of 24) and structure phase were obtained by SOLVE. (Terwilliger, T. C. & Berendzen, J. (1999). Automated MAD and MIR structure solution. Acta Crystallogr D Biol Crystallogr 55, 849-61.) Density modification by solvent flattening was carried out by RESOLVE (Terwilliger, T. C. & Berendzen, J. (1999). Acta Crystallogr D Biol Crystallogr 55, 849-61) to generate an interpretable 3.3 Å electron density map. The model was manual built using COOT. (Emsley, P. & Cowtan, K. (2004). Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60, 2126-32) This model was subsequently refined to 2.16 Å resolution by using a native dataset. PHENIX was used at the initial refinement process, with the group atomic displacement parameter, and TLS options turned on. (Adams, P. D., Grosse-Kunstleve, R. W., Hung, L. W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K. & Terwilliger, T. C. (2002). PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr 58, 1948-54.) A final run of refinement was achieved with REFMAC5. (Murshudov, G. N., Vagin, A. A. & Dodson, E. J. (1997). Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53, 240-55.) TLS groups were determined by TLSMD server. (Painter, J. & Merritt, E. A. (2006). Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr D Biol Crystallogr 62, 439-50.)

Example 3 Molecular Dynamics Simulation

GROMACS (Van Der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E. & Berendsen, H. J. (2005). GROMACS: fast, flexible, and free. J Comput Chem 26, 1701-18) was used as the molecular dynamics simulation engine. MARTINI force field (Marrink, S. J. & Mark, A. E. (2004). Molecular view of hexagonal phase formation in phospholipid membranes. Biophys J 87, 3894-900) was used to model the coarse-grained PBP1b structure. After converting the atomic model into coarse-grained model, the structure was subjected to a brief steepest-descent energy minimization. It was then manually inserted into a water box containing pre-equilibrated lipid bilayer. A initial orientation of PBP1b were chosen subjectively to see if the final orientations would equilibrate to a specific position. Seven chloride ions were added into the box in order to maintain electrostatic neutrality. A steepest-descent energy minimization was carried out to relax any steric conflict between protein, lipid molecules, ions and solvent before the MD run. During the MD simulation, the secondary structure and the overall fold of PBP1b was restrained by using elastic network model. (Atilgan, A. R., Durell, S. R., Jernigan, R. L., Demirel, M. C., Keskin, 0. & Bahar, I. (2001) Anisotropy of fluctuation dynamics of proteins with an elastic network model. Biophys J 80, 505-15)

In the production run, the time step for integration was set to 20 fs. The non-bonded neighbor list was updated every 10 steps. The simulations were performed at constant temperature, pressure and number of particles (NPT ensemble). The temperature of protein, lipid molecules, ions and solvent were coupled separately at 320 K using Berendsen algorithm (Berendsen, H. J. C., Postma, J. P. M., Vangunsteren, W. F., Dinola, A. & Haak, J. R. (1984). Molecular-Dynamics with Coupling to an External Bath. Journal of Chemical Physics 81, 3684-3690) with a coupling constant T _(t)=40 ps. The system pressure was semi-isotropically coupled to using Berendsen algorithm at 1 bar with a coupling constant T _(p)=40 ps and a compressibility of 1×10⁻⁵ bar.

Example 4 Fluorescence Anisotropy Measurements

Fluorescence anisotropy measurements were carried out in triplicates in the wells of 384-well or 1536-well plates using a fluorescence detector that is capable to measure fluorescence anisotropy or fluorescencepolarization. For examples, a laser fluorimetry equipped with a 488 nm laser (IsoCyte) from Blueshift Biotech, Inc., (Sunnyvale, Calif., USA) of a Viewlux from Perkin Elmer has been used for the application. Various buffers, salts, pH values, and divalent cations (Ca⁺⁺, Mg⁺⁺, Co⁺⁺) were optimized for fluorescence anisotropy measurements. K_(D) and K_(I) determinations were carried out in 100 mM NaCl, 10 mM Tris, pH 8.0. Fluorescence anisotropy values (A) were calculated using the equation: A=(I∥−G*I^(⊥))/(I∥+2G*I^(⊥)), where I∥ is the fluorescence intensity of emitted light parallel to excitation, I^(⊥) is the fluorescence intensity of emitted light perpendicular to excitation, and G is the gating factor that corrects for instrument bias. The G factor is experimentally determined for each run using the probe-only well as the basal anisotropy.

Candidate compounds to be tested were labeled with fluorescein (6-carboxyfluoresein N-hydroxysuccinimide ester) under basic conditions to prepare the fluorescent probe. One major concern about the fluorescent probe used in the FA assay is the probe itself; either the fluorophore or the structure modification, may interfere with the binding between the targeted protein and the small molecule. Therefore, the PBP binding affinities of Moe A and the fluorescent probe are compared using SPR. The determined steady-state affinity (K_(D)) values are similar for Moe A and F-Moe (4.4×10⁻⁷ vs. 5.2×10⁻⁷M).

A high-throughput FA assay for transglycosylase was performed as disclosed in co-pending U.S. application Ser. No. 12/354,717. Concentration-dependent changes in fluorescence anisotropy was observed when E. coli PBP1b bound to F-Moe. The maximum anisotropy value was 0.2. The displacement of the PBP1b bound F-Moe complex by unlabeled candidate agents at various concentrations is measured by changes in fluorescence anisotropy is defined as [(A_(obs)−A_(min))/(A_(max)−A_(min))×100%]. The anisotropy of F-Moe increased significantly by incubation with E. coli PBP1b, supposedly due to the formation of F-Moe-PBP1b complex. In contrast, the anisotropy of F-Moe is unchanged when incubated with bovine serum albumin, up to 100 μM.

For the development of an assay for inhibitor screening, F-Moe was preincubated with E. coli PBP1b and then competed with unlabeled Moe A at various concentrations. A decrease in anisotropy was used to validate the FA assay to screen for inhibitors that displace the probe competitively from the moenomycin binding pocket of PBP1b.

K_(I) and IC₅₀ values were determined from competitive displacement assay. For displacement assay, the initial condition contained 40 μl of 100 nM F-Moe, 10 μg/ml E. coli PBP1b in 10 mM Tris, pH 8.0, 100 mM NaCl for 384-well assays, or 10 μl of 100 nM F-Moe, 50-100 μg/ml E. coli PBP1b in 10 mM Tris, pH 8.0, 100 mM NaCl for 1536-well plates. Aliquots of compound stock solution were added and the anisotropy was monitored after 5 minutes of equilibration. The data from the displacement assay was used to calculate the inhibition constant (K_(I)) and IC₅₀ value of an inhibitor using the complete competitive binding model.

Example 5 High-Throughput Screening for Transglycosylase Inhibitors

The FA assay was used to screen against 50,000 purchased small molecules (ChemBridge Inc., San Diego, Calif., USA) and 7,000 from proprietary collections. The compounds were transferred to 96-well plates (Freedom Evo, Tecan Schweiz A G, Männedorf, Switzerland) and then to 384-well plates using a multi-dispenser (Labcyte, Sunnyvale, Calif., USA) to prepare the compound plates for screening. The E. coli PBP1b (10 μg/ml) in 100 nM F-Moe, 10 mM Tris, 100 mM NaCl, pH 8.0 at a final volume of 40 μl was added to 384-well plates (Freedom Evo 150, Tecan). One μl of 2 mM compound stocks were added to wells using a multi-dispenser (Labcyte). The last two columns of every plate were controls with 10 μM moenomycin and 2.5% DMSO, respectively. After a 30-minute incubation, changes in fluorescence anisotropy were determined with Isocyte (Blueshift Biotech Inc). Hits that showed greater than 75% reduction compared to the control anisotropy values were selected for further confirmation.

Example 6 Determination of Minimal Inhibitory Concentration (MIC)

The minimal inhibitory concentration (MIC) of tested compounds was determined following the NCCLS standard. The experiments were conducted in 96-well microtiter plates using two-fold dilutions in Muller-Hilton broth with (Streptococcus pneumonia) or without blood (Bacillus subtilis, Enterococcus faecalis, Staphylococcus aureus, Escherichia coli, MRSA, Actinetobacter baumannii, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Mycobacterium smegmatis). Exponentially growing cells at 5×10⁵ cells/ml were incubated with test compounds at various concentrations. After an 18 h to 24 h incubation at 37° C., MIC was determined as the minimal concentration of the compound that prevents bacterial growth.

Example 7 Lipid II Polymerization Assay

Lipid II polymerization assays were carried out by incubating 100 μM fluorophore-labeled lipid II and penicillin-binding protein 1b from E. coli in tubes containing 10 ng/μL N-acetyl muramidase in 50 mM Tris•HCl (pH 8.0), 10 mM MgCl₂, 0.1% Triton X-100, 10% DMSO, and 15% MeOH for 30 minutes (Van Nieuwenhze et al. J Am Chem Soc 2002, 124, 3656.). The fluorophore can be dansyl chloride, NBD, BODIPY, fluorescein. Reaction supernatants were then injected onto an anion-exchange HPLC column (SAX1, Supelco Co.) and eluted with a linear gradient of ammonium acetate (20 mM to 0.5 M) in methanol. The eluant was monitored for fluorescence with λ_(ex)=466 nm and λ_(em)=535 nm.

Micrococcus flavus vesicles (6.4 mg) were incubated with 100 mM UDP-MurNAc, 200 mM UDP-GlcNAc, 10 mg undecaprenyl monophosphate in buffer (50 mM Tris-HCl, pH 8, 10 mM MgCl₂, and 1% (w/v) Triton X-100) with a final volume of 100 μL (Breukink et al. J Biol Chem 2003, 278, 19898.). The suspension was sonicated at 30° for 20 min and evaporated to dryness. The crude mixture was purified by normal phase chromatography, followed by reverse phase HPLC on a Zorbax RX-C8 column (9.4 mm×250 mm, 5μ) using a gradient elution of 85:15 v/v (methanol: ammonium bicarbonate) to 100% methanol over 60 min at a flow rate of 1 mL/min. The retention time of the desired product was 27 min (detection at UV 220 nm). Lyophilization of the pure fractions gave lipid II (1.1 mg, 6.1% yield from UDP-MurNAc). HRMS (ESI) calcd for [C₉₄H₁₅₆N₈O₂₆P₂-2H]²⁻ 936.5349, found 936.5343.

A transglycosylase assay was performed in situ as follows. Fifty μl aliquots of the lipid II reaction (above) were used as a source of preformed lipid II and transglycosylase enzymes. Either 7.5 μl of DMSO or 7.5 μl of inhibitor in DMSO was added and preincubated for 10 min. Triton X-100 was removed by addition of 35 μl of a suspension of detergent binding resin (Detergent-Out resin, Geno Technology, St. Louis, Mo., USA), followed by incubation for an additional 2 h at room temperature. The total aqueous volume in the reaction was approximately 75 μl. After the 2-h incubation, 100 μl of 10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.2% Triton X-100 was added to each reaction. Thirty-five μl of the reactions were spotted onto Whatman 3MM paper for chromatography.

The amount of lipid II formed as a precursor and the amount of peptidoglycan generated as a result of the in situ transglycosylase reaction were determined by paper chromatography according to standard methods. (Branstrom, A. A., Midha, S., Longley, C. B., Han, K., Baizman, E. R., Axelrod, H. R. (2000) Assay for identification of inhibitors for bacterial MraY translocase or MurG transferase. Anal. Biochem. 280, 315-319.)

Example 8 Transglycosylase (TG) Activity Assay

Purified protein was concentrated in 20 mM Tris-HCl (pH 8.0), 300 mM NaCl, and 1 mM DDM. Instead of using Dansyl lipid II, 6-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino) hexanoyl (NBD)-labeled Lipid II was prepared as described (Taubes G (2008) Science 321:356-361; Payne D J (2008) Science 321:1644-1645) and used as a substrate to measure TG enzymatic activity, with approach similar to what has been described previously (Holtje N (1998) Microbiol Mol Biol Rev 62:181-203). Assays were carried out by using the following condition: NBD-Lipid II, 20 nM protein, 50 mM Tris HCl (pH 8.0), 10 mMCaCl2, 0.085% decyl PEG (Anatrace), and 15% MeOH at 37° C. for 0, 1, 3, 5, 7, 9, 20, and 30 min. The concentration of NBD-Lipid II was varied from 1 to 100 μM to determine the rate of the TG activity. After the reaction, 200 μM moenomycin was added to stop the reaction, and 13 μM muramidase (Sigma-Aldrich) was added to digest the TG products to result in NBD-Lipid II without lipid tails. The fluorescent signal decrease of substrate and increase of NBD-Lipid II without lipid tails were detected by anion-exchange column SAX1 (Supelco) on HPLC (Hitachi). The elution procedures was a linear gradient of ammonium acetate (20 mM to 1 M) in MeOH monitored at λ_(excitation)=466 nm and λ_(emission)=535 nm. The kinetic parameter was estimated by following the Michaelis-Menten equation. To investigate the importance of transmembrane (TM) helix, PBP1b and PBP1bΔTM (residues Met-1 to Leu-87 were removed) were extracted with the buffer containing 20 mM Tris-HCl (pH 8.0), 300 mM NaCl, and 13 mM FOS-CHOLINE-14 (Anatrace). The protein was purified by nickel chelation chromatography in the presence of 1 mM DDM. The activity assay was carried out by using the following condition: 12 μM NBD-Lipid II, 20 nM protein, 50 mM Tris-HCl (pH 8.0), 10 mM CaCl₂, 0.085% decyl PEG, and 15% MeOH at 37° C. for time 0, 1, 3, 5, 7, 9, 20, and 30 min. The initial velocity was used to compare the activity of full-length PBP1b and PBP1bΔTM.

Example 9 Pull-Down Assay

Purified PBP1b variants (including full-length PBP1b, PBP1bΔUB2H, and UB2H only) and UvrB were coupled with CNBr-activated Sepharose™ (GE LifeSciences). A control Sepharose™ without proteins was treated in the same procedure. His tagged MltA, PBP3, FtsN, and UvrA were overexpressed in BL21(DE3) cells at 37° C. for 3 h. Overexpressed cells were extracted in lysis buffer [10 mM Tris (pH 6.8), 10 mM sodium maleate (Sigma-Aldrich), 10 mM MgCl2, and 2% Triton X-100] at 4° C. overnight and then centrifuged at 20,000×g for 30 min at 4° C. The resulting supernatant, the detergent-solubilized membrane fractions, was incubated with PBP1b variants-coupled Sepharose™ beads at 4° C. overnight. Beads were washed with lysis buffer 30 times column volume (CV) and further washed with 5 CV lysis buffer supplemented with 150 mM NaCl. The interacting protein was eluted with lysis buffer containing 1.0 M NaCl. The eluate was analyzed by Western blotting with anti-His antibody.

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims. 

1. A method for identifying a potential transglycosylase (peptidoglycan glycosyltransferase) inhibitor compound, the method comprising the steps of: a) using a three-dimensional structure of E. coli Penicillin binding protein 1b (PBP1b) as defined by atomic coordinates according to FIGS. 8-1 through 8-117; b) employing said three-dimensional structure to design or select said potential inhibitor such that said potential inhibitor is capable of binding to at least one amino acid in an active site of PBP1b transglycosylase; c) synthesizing the potential inhibitor; d) in an assay, contacting the potential inhibitor with the PBP1b transglycosylase in the presence of lipid II, or derivative thereof; and e) determining the PBP1b transglycosylase inhibitory activity of the potential inhibitor.
 2. The method of claim 1, wherein the potential transglycosylase inhibitor is designed or selected using computer modeling.
 3. The method of claim 1, wherein the potential transglycosylase inhibitor is designed de novo.
 4. The method of claim 1, wherein the potential transglycosylase inhibitor is designed based on a known inhibitor.
 5. The method of claim 4, wherein the known inhibitor is moenomycin A.
 6. The method of claim 1, wherein the transglycosylase active site comprises one or more of the amino acid residues E114, E171, E233, E290, S398, and S510.
 7. The method of claim 1, wherein the inhibitor-binding site comprises one or more of residues Thr269, Val273, Phe277, Tyr315, Gln318, Lys355, Gly356, and Ser 358 residues of PBP1b.
 8. The method of claim 1, wherein the inhibitor-binding comprises a hydrogen-bonding interaction with one or more of Glu233, Gln271, Asn275, Lys355, Arg286, Glu290 and Ser358 residues of E. Coli PBP1b.
 9. The method of claim 7, wherein the inhibitor-binding site comprises amino acid residues from at least one of transglycosylase (TG), UvrB domain 2 homolog (UB2H) and transmembrane (TM) domains of PBP1b.
 10. The method of claim 1, wherein the inhibitor prevents peptidoglycan elongation by structurally mimicking lipid IV at the binding site of transglycosylase.
 11. A method of using a co-crystal of an E. coli PBP1b transglycosylase enzyme with moenomycin A for screening for a novel drug capable of inhibiting a transglycosylase (peptidoglycan glycosyltransferase), the method comprising wherein said crystal effectively diffracts X-rays for the determination of the atomic coordinates of said PBP1b-moenomycin complex to a resolution of greater than 2.16 Å, and according to FIGS. 8-1 through 8-117, and wherein said method comprises: a) selecting a potential ligand by performing rational drug design with the three-dimensional structure of the moenomycin binding site determined for the crystal; b) in an assay, contacting the potential ligand with the ligand binding domain of the enzyme; and c) detecting the binding potential of the potential ligand for the ligand binding domain, wherein the potential ligand is selected as a novel drug based on the potential ligand having a greater affinity for the ligand binding domain than that of a known drug.
 12. The method of claim 11, wherein the potential transglycosylase inhibitor is designed or selected using computer modeling.
 13. The method of claim 11, wherein the potential transglycosylase inhibitor is designed de novo.
 14. The method of claim 11, wherein the potential transglycosylase inhibitor is designed based on a known inhibitor.
 15. The method of claim 14, wherein the known inhibitor is moenomycin A.
 16. The method of claim 11, wherein the affinity of the inhibitor for PBP1b is determined by a fluorescence anisotropy assay.
 17. The method of claim 11, wherein the inhibitor-binding site comprises one or more of moenomycin-binding residues Thr269, Val273, Phe277, Tyr315, Gln318, Lys355, Gly356, and Ser 358 residues of PBP1b.
 18. The method of claim 17, wherein the inhibitor binding further comprises a hydrogen-bonding interaction with one or more of Glu233, Gln271, Asn275, Lys355, Arg286, Glu290 and Ser358 residues of E. Coli PBP1b.
 19. The method of claim 17, wherein the inhibitor-binding site comprises amino acid residues from at least one of transglycosylase (TG), UvrB domain 2 homolog (UB2H) and transmembrane (TM) domains of PBP1b.
 20. The method of claim 11, herein the inhibitor inhibits peptidoglycan elongation by structurally mimicking lipid IV at the binding site of transglycosylase.
 21. A method of evaluating the binding properties of a potential PBP1b transglycosylase inhibitor compound comprising the steps of: (a) co-crystallizing said compound with PBP1b; (b) determining the three-dimensional structure of said PBP1b-potential inhibitor complex co-crystal by molecular replacement using the three-dimensional structure of PBP1b as defined by atomic coordinates according to FIGS. 8-1 through 8-117; and (c) analyzing said three-dimensional structure of said PBP1b bound to said potential inhibitor compound to evaluate the binding characteristics of said potential inhibitor compound.
 22. A method for identifying a potential inhibitor compound for E. coli Penicillin binding protein 1b (PBP1b) transglycosylase, the method comprising the steps of: (a) providing a candidate agent; (b) in an anisotropy measurement assay, determining an effectiveness of the candidate agent to bind PBP1b; and (c) in a transglycosylation assay, contacting the candidate agent with the PBP1b transglycosylase in the presence of lipid II, or derivative thereof, and determining a PBP1b transglycosylase inhibitory activity of the candidate agent.
 23. The method of claim 22, further comprising: (d) co-crystallizing said candidate agent with PBP1b; (e) determining the three-dimensional structure of the co-crystal of said PBP 1b-candidate agent complex by comparing with the three-dimensional structure of PBP1b-moenomycin as defined by atomic coordinates according to FIGS. 8-1 through 8-117; and (f) analyzing said three-dimensional structure of said PBP1b bound to said candidate agent to evaluate the binding characteristics of said potential inhibitor compound.
 24. The method of claim 22, wherein the candidate agent is a compound of the formula:


25. The method of claim 24, wherein the candidate agent is selected from the group consisting of: (a) a compound of the formula (WCKTS-A1N1):

and (b) a compound of the formula (WCKTS-A1N3):


26. The method of claim 22, wherein the candidate agent has the formula:

wherein R¹═Br, Cl, I, H or OH; R²═H, OH or Cl; R³═Br, Cl, I, H, or

R⁴═H, OH, Cl,

R⁵═H, Cl,

R⁶═H, CH₃, OH, OCH₃, C₁, NO₂, or

R⁷═H, Cl,


27. The method of claim 26, further comprising: (d) selecting a candidate agent that binds PBP1b, and exhibits transglycosylase activity; (e) co-crystallizing said candidate agent with PBP1b; (f) determining the three-dimensional structure of said PBP1b-candidate agent complex co-crystal by comparing the three-dimensional structure of PBP1b-moenomycin as defined by atomic coordinates according to FIGS. 8-1 through 8-117; and (g) analyzing said three-dimensional structure of said PBP1b bound to said candidate agent to evaluate the binding characteristics of said potential inhibitor compound.
 28. The method of claim 27, wherein the binding comprises one or more interactions with amino acid residues from transglycosylase (TG), UvrB domain 2 homolog (UB2H) or transmembrane (TM) domains of PBP1b.
 29. An anti-bacterial compound comprising the formula:

wherein the compound (a) binds PBP1b, and (b) exhibits transglycosylase activity.
 30. The anti-bacterial compound of claim 29, wherein the compound is effective in inhibiting the growth of at least one of Staphylococcus aureus (ATCC29213, SA), methicillin-resistant Staphylococcus aureus (ATCC33592, MRSA), Mycobacterium smegmatis (ATCC11565, MS), and Escherichia coli (ATCC 25922, EC), Streptococcus pneumonia, Bacillus subtilis, Enterococcus faecalis, Acinetobacter baumannii, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Aquifex aeolicus.
 31. The anti-bacterial compound of claim 29, wherein, in a co-crystal of the compound with PBP1b, the compound contacts the moenomycin-binding site of PBP1b as defined by atomic coordinates according to FIGS. 8-1 through 8-117.
 32. The anti-bacterial compound of claim 29, wherein the compound is selected from the group consisting of: (a) WCKTS-A1N1 having the formula:

and (b) WCKTS-A1N1 having the formula:


33. The anti-bacterial compound of claim 32, wherein, in a co-crystal of the compound with PBP1b, the compound contacts the moenomycin-binding site of PBP1b as defined by atomic coordinates according to FIGS. 8-1 through 8-117.
 34. The compound of claim 29 wherein the PBP1b binding is determined by an anisotropic assay.
 35. The compound of claim 34, wherein the anisotropic assay is a fluorescent anisotropic assay.
 36. The compound of claim 29 wherein the transglycosylase activity is determined by a polymerization assay using lipid II, or a derivative thereof.
 37. An anti-bacterial compound having the formula:

wherein R¹═Br, Cl, I, H or OH; R²═H, OH or Cl; R³═Br, Cl, I, H, or

R⁴═H, OH, Cl,

R⁵═H, Cl,

R⁶═H, CH₃, OH, OCH₃, C₁, NO₂, or

R⁷═H, Cl, and

wherein the compound (a) binds PBP1b, and (b) exhibits transglycosylase activity.
 38. The anti-bacterial compound of claim 37, wherein, in a co-crystal of the compound with PBP1b, the compound contacts the moenomycin-binding site of PBP1b as defined by atomic coordinates according to FIGS. 8-1 through 8-117.
 39. The compound of claim 37 wherein the PBP1b binding is determined by an anisotropic assay.
 40. The compound of claim 39, wherein the anisotropic assay is a fluorescent anisotropic assay.
 41. The compound of claim 37 wherein the transglycosylase activity is determined by a polymerization assay using lipid II, or a derivative thereof.
 42. The compound of claim 37, wherein the binding of the compound to E. coli PBP1b comprises binding to at least one portion of the transmembrane (TM) domain of PBP1b.
 43. The compound of claim 37, wherein the binding of the compound to E. coli PBP1b comprises binding to at least one portion of the UvrB domain 2 homolog (UB2H) domain of PBP1b.
 44. The compound of claim 43, wherein the UB2H binding further inhibits cell wall synthesis.
 45. The compound of claim 43, wherein the UB2H binding further inhibits DNA repair.
 46. The compound of claim 37, wherein the compound prevents peptidoglycan elongation by structurally mimicking lipid IV at the binding site of transglycosylase.
 47. The compound of claim 37, wherein the compound inhibits a peptidoglycan glycosyltransferase.
 48. The compound of claim 47, wherein the peptidoglycan glycosyltransferase is PBP1b, SaPBP2 or AaPGT.
 49. The compound of claim 37, wherein the compound comprises a pharmaceutical composition. 